Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) have been given an average rating of "Buy" by the nine analysts that are covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $18.86.
Several research firms have recently commented on ORIC. Guggenheim reaffirmed a "buy" rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Thursday, March 20th. JPMorgan Chase & Co. upped their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, January 14th.
Read Our Latest Stock Report on ORIC
Hedge Funds Weigh In On ORIC Pharmaceuticals
A number of large investors have recently bought and sold shares of ORIC. Charles Schwab Investment Management Inc. lifted its position in shares of ORIC Pharmaceuticals by 152.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company's stock worth $4,205,000 after purchasing an additional 247,863 shares in the last quarter. Barclays PLC grew its holdings in shares of ORIC Pharmaceuticals by 111.2% in the 3rd quarter. Barclays PLC now owns 107,261 shares of the company's stock valued at $1,100,000 after acquiring an additional 56,474 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of ORIC Pharmaceuticals by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company's stock valued at $9,067,000 after acquiring an additional 196,804 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of ORIC Pharmaceuticals by 3.8% in the third quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company's stock valued at $361,000 after acquiring an additional 1,279 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in ORIC Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock worth $109,000 after acquiring an additional 2,520 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.
ORIC Pharmaceuticals Stock Performance
Shares of ORIC stock traded down $0.05 on Friday, hitting $5.53. The stock had a trading volume of 1,257,467 shares, compared to its average volume of 615,574. ORIC Pharmaceuticals has a 52-week low of $5.26 and a 52-week high of $14.67. The firm has a market capitalization of $392.78 million, a price-to-earnings ratio of -3.04 and a beta of 1.25. The stock's 50 day moving average is $8.57 and its 200-day moving average is $9.06.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.01. Equities analysts expect that ORIC Pharmaceuticals will post -2.17 earnings per share for the current year.
ORIC Pharmaceuticals Company Profile
(
Get Free ReportORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Further Reading
Before you consider ORIC Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ORIC Pharmaceuticals wasn't on the list.
While ORIC Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
